Notably, reduced levels of Bacteroides and LPC have been observed in patients with cognitive impairment, suggesting that targeting the Bacteroides-LPC-GPR119-ferroptosis signaling axis may offer therapeutic strategies for cognitive disorders [12]. The gene discussed is GPR119; the disease is Cognitive impairment.